You have done the work. You showed up to appointments, filled the prescriptions, waited the weeks your doctor recommended, and tried again when the first option did not hold. If you are reading this from Middletown Township or somewhere nearby in Monmouth County, still searching for relief, what you are experiencing has a name — treatment-resistant depression — and it is more common, more treatable, and less a reflection of your character than the journey so far may have led you to believe. Approximately one-third of people treated for major depressive disorder do not achieve remission after initial antidepressant treatment steps, representing many patients who need different tools (Rush et al., 2006; Gaynes et al., 2020).
What Defines Treatment-Resistant Depression
In clinical terms, treatment-resistant depression (TRD) is typically defined as a major depressive episode that has failed to respond to at least two antidepressant trials of adequate dose and adequate duration — generally at least four to six weeks at therapeutic dosing (Gaynes et al., 2020). This threshold is not arbitrary; it reflects the evidence base for what constitutes a genuine trial of each medication class.
In practice, TRD often means something more than a clinical definition. It means years of trying. It can mean SSRIs, SNRIs, augmentation with atypical antipsychotics, combinations, electroconvulsive therapy consultations, and still waking up each morning without feeling like yourself. The weight of that history — of hope offered and then withdrawn — is its own burden, separate from the depression itself.
Recognizing TRD early matters. The longer a depressive episode persists without remission, the more important it becomes to reassess whether the current treatment pathway is still the right one. Our guide on what to ask your doctor when depression treatment isn’t working can help you prepare for that conversation. Discuss with your provider whether a formal TRD evaluation is the appropriate next step for your care.
The Neuroscience Behind Why Standard Antidepressants Fail Some Patients
Most conventional antidepressants work by modifying monoamine neurotransmitter levels — primarily serotonin, norepinephrine, and dopamine. For many patients, this approach is effective. But for a significant subset of people with TRD, researchers have focused increasing attention on different pathways, including the glutamatergic system, which is involved in synaptic plasticity and the brain’s capacity to form new connections.
Chronic depression is associated in some research with changes in synaptic connectivity and stress-sensitive brain regions involved in mood regulation, cognitive flexibility, and emotional processing (Duman et al., 2016). Monoamine-targeting medications do not directly target these glutamate-related mechanisms in the same way. Glutamate-targeting treatments — including IV ketamine and SPRAVATO® — are being used because they act on NMDA receptor pathways and downstream processes that may influence synaptic plasticity and brain-derived neurotrophic factor (BDNF) signaling (Castrén & Monteggia, 2021).
A landmark clinical trial demonstrated that IV ketamine produced rapid antidepressant effects in patients with treatment-resistant major depression, supporting NMDA receptor modulation as a meaningful treatment pathway in TRD (Murrough et al., 2013). This is a mechanism of action that differs from standard antidepressants. Results vary by individual, and not every patient with TRD will respond equally. To understand more about how this process works, see our overview of ketamine for depression: how it works.
Interventional Options Available at Allevate Health Middletown
At our Middletown Township location, we offer two primary interventional options for patients with treatment-resistant depression, alongside comprehensive treatment.
IV Ketamine Therapy delivers ketamine directly into the bloodstream, allowing for precise dosing and immediate bioavailability. An initial series is administered in our medically supervised setting, with monitoring by our clinical team. IV ketamine for psychiatric indications is considered off-label, and candidacy requires a thorough medical and psychiatric evaluation. Ketamine injection is FDA-approved as an anesthetic, but not specifically FDA-approved for depression (DailyMed, n.d.).
SPRAVATO® (esketamine) is FDA-approved for treatment-resistant depression in adults and is administered as a nasal spray in a certified clinical setting (U.S. Food and Drug Administration, 2025). Sessions are supervised, and you remain in our care for at least two hours following administration for monitoring. SPRAVATO® is covered by many insurance plans for patients with confirmed TRD who meet clinical criteria.
Barriers to Care
Accessing specialized TRD care near Middletown, NJ can feel difficult when most available referrals point toward general psychiatry practices without interventional capabilities. Our Middletown Township location was established to reduce this barrier for patients in Monmouth County — bringing IV ketamine and SPRAVATO® to a community where demand for these treatments is real and growing.
Skepticism after repeated treatment failures is completely understandable. When you have tried many things and none have held, protecting yourself from another disappointment is a rational response. We do not ask patients to arrive with hope they do not have. We do ask for honesty — about your history, your goals, and your concerns — so that we can give you an equally honest clinical assessment of whether interventional treatment is appropriate for your situation.
Preparing for a Consultation
A complimentary consultation at Allevate Health Middletown begins with a thorough review of your psychiatric and medical history. Come prepared to discuss your prior medication trials, dosing, duration, and what your response was to each. Bring records if you have them, but even a clear verbal history is a useful starting point. Our guide to preparing for a ketamine therapy consultation can help you organize what to bring and what questions to ask.
We review your current medications for potential interactions, evaluate any medical contraindications, and walk you through realistic expectations for whichever treatment may be the right fit. If ketamine-based therapy is recommended, our article on what medically supervised ketamine therapy means can also help you understand why monitoring and clinical oversight matter.
You are not starting over. Your history is information — and the more complete it is, the more precisely we can evaluate what may help. Call 848-345-5831 or schedule a consultation at our Middletown Township location today.
Frequently Asked Questions
How do I know if I have treatment-resistant depression?
The clinical threshold is typically defined as an inadequate response to two or more antidepressant trials of adequate dose and duration. Your prescribing physician or psychiatrist can formally evaluate your history against TRD criteria. If you are unsure whether your case qualifies, we can help review your history during a complimentary consultation.
Can I receive TRD treatment while continuing to see my psychiatrist?
Yes. We strongly encourage coordination with your existing mental health providers. We communicate with your care team as appropriate and design treatment plans that complement rather than replace your ongoing psychiatric care.
Is IV ketamine or SPRAVATO® better for TRD?
Both are supported by clinical evidence for TRD, and both work through glutamate-related pathways. The choice depends on your medical history, insurance coverage, scheduling needs, prior treatment history, and whether your diagnosis fits SPRAVATO®’s FDA-labeled indications. We discuss both options in detail during your consultation so you can make an informed decision.
What happens if I respond initially but depression returns?
TRD treatment is rarely a one-time event. Maintenance protocols — whether periodic booster infusions, adjusted SPRAVATO® frequency, or additional treatment — are part of the individualized care plan we build with you. Response patterns are monitored closely and plans are adjusted accordingly.
Are there risks I should know about?
Both ketamine and SPRAVATO® carry a risk profile that can include transient dissociation, elevated blood pressure during sessions, nausea, dizziness, or sedation. SPRAVATO® also has specific REMS monitoring requirements due to risks including sedation, dissociation, respiratory depression, abuse, and misuse (U.S. Food and Drug Administration, 2025). These effects are managed in our medically supervised setting. A thorough evaluation prior to treatment identifies any factors that may increase risk and guides candidacy decisions.
Key Takeaways
Approximately one-third of people treated for major depressive disorder do not achieve remission after initial antidepressant treatment steps (Rush et al., 2006; Gaynes et al., 2020).
Treatment-resistant depression is commonly defined by failure to respond to two or more adequate antidepressant trials — it is a clinical condition, not a personal failing.
Glutamate-targeting treatments like IV ketamine and SPRAVATO® work through mechanisms distinct from conventional monoamine-targeting antidepressants.
IV ketamine and SPRAVATO® are both available at Allevate Health Middletown in a medically supervised setting.
A complimentary consultation allows us to evaluate whether interventional treatment is appropriate for your specific history, treatment goals, and safety profile.
References
Castrén, E., & Monteggia, L. M. (2021). Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biological Psychiatry, 90(2), 128–136. https://doi.org/10.1016/j.biopsych.2021.05.008
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nature Medicine, 22(3), 238–249. https://doi.org/10.1038/nm.4050
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman-Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., Coker-Schwimmer, E., Viswanathan, M., & Lohr, K. N. (2020). Defining treatment-resistant depression. Depression and Anxiety, 37(2), 134–145. https://doi.org/10.1002/da.22968
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D. S., & Mathew, S. J. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134–1142. https://doi.org/10.1176/appi.ajp.2013.13030392
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
U.S. Food and Drug Administration. (2025). SPRAVATO® (esketamine) nasal spray, CIII prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy, SPRAVATO®, and treatment should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.